Navigation Links
Transition Therapeutics to Present at Cowen & Company 28th Annual Healthcare Conference
Date:3/18/2008

TORONTO, March 18 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH, NASDAQ:TTHI) today announced that Dr. Tony Cruz, Chairman and Chief Executive Officer, will present at the upcoming Cowen & Company 28th Annual Health Care Conference. Dr. Cruz's presentation will take place on Wednesday, March 19, 2008 at 8:00 A.M. (Eastern Time) at the Boston Marriott Copley Place.

About Transition

----------------

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 (AZD-103) for the treatment of Alzheimer's disease and TT-223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally and developed internally using its proprietary drug discovery engine. Transition's shares are listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For additional information about the Company, please visit http://www.transitiontherapeutics.com.

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the OSC, SEC or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including conducting clinical trials. These statements are based upon the current expectations and beliefs of Transition's management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include factors beyond Transition's control and the risk factors and other ca
'/>"/>

SOURCE Transition Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
2. Transition Therapeutics Receives Remaining Upfront Payment from Elan Corporation, plc
3. Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2008 Financial Results on Wednesday, November 14, at 8:30 A.M. EST
4. New UIC center to study end-of-life transition
5. Seabrook House Opens Transitional Living Facility: Seabrook West
6. Transition Therapeutics Announces Milestone Payment from Elan
7. Transition Therapeutics Announces Appointment of Vice-President of Business Development
8. Pure Weight Loss Takes Additional Steps To Assure Seamless Transition For Clients
9. Zimmer Spine Introduces New Rigid to Dynamic Stabilization Transition System
10. Bisexuality not a transitional phase among women, according to new research
11. Transition of Behavioral Health Services from WPIC-BV to Heritage Valley Health System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... three Ebola cases in Dallas. But, mental health specialists say ... President Barack Obama on Friday appointed an Ebola "czar" ... infected two Dallas nurses who cared for a Liberian man ... Hospital. But the U.S. cases are miniscule in the ...
(Date:10/22/2014)... Los Angeles, California (PRWEB) October 22, 2014 ... Recovery 2.0: Move Beyond Addiction and Upgrade Your Life (Paperback; ... the field of Yoga & Recovery. This book is ... and thrive in a life of recovery. , Recovery ... of the 12 Steps; Recovery 2.0 is a guide for ...
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... 2014 Richard Carlson, Managing Partner of ... with over 25 years experience. Mr. Carlson is ... areas related to EDI, B2B Commerce, RFID and Internet/Intranet ... Advisory Board member for Pharmaceutical Commerce Magazine and a ... Group is a management and technology consulting firm focused ...
(Date:10/22/2014)... (HealthDay News) -- Two sisters in high school have ... Ilina and Medha Krishen use electronic stethoscopes, which electronically ... in breathing patterns or heartbeats. Ilina, a senior ... to find a way to detect early lung damage ... electronic stethoscope, Ilina recorded one breath cycle each from ...
Breaking Medicine News(10 mins):Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2
... /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotheropeutics, Inc., ... develops novel drug targets that disrupt the advance ... Dr. Anders Boegh Jensen to its Scientific Advisory ... his considerable expertise in biotechnology and molecular biology ...
... to better treatment decisions for respiratory infections, experts say , ... may be able to help doctors determine which patients need ... in the Sept. 9 issue of the Journal of ... test resulted in less antibiotic use. , If the protocol ...
... , NEW BRUNSWICK, N.J., Sept. 8 Johnson ... Morgan Stanley Global Healthcare Unplugged Conference on Tuesday, September 15th, at ... Surgical Care for Johnson & Johnson, will represent the Company in ... This broadcast will be available to interested investors and ...
... , , LOS ... Dr. Christina Restrepo has achieved diplomate status with the American College ... Restrepo graduated in 2003 from the University of Florida College of ... small animal medicine and surgery at the renowned Animal Medical Center ...
... , RANCHO CORDOVA, Calif., Sept. 8 ThermoGenesis ... that process and store adult stem cells, announced today it will report ... ended June 30, 2009, on Wednesday, September 9, 2009. , , ... Management will host a conference call Wednesday, September 9, 2009 at 2:00 ...
... , , ... Chemistry September 15 at UC Berkeley Campus , , ... hazardous chemicals in the air and water have led scientists to ... troubling health effects are associated with endocrine disrupting chemicals (EDCs) that ...
Cached Medicine News:Health News:GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board 2Health News:Blood Test Narrows Down Need for Antibiotics 2Health News:Blood Test Narrows Down Need for Antibiotics 3Health News:Animal Dermatology Clinic Marina del Rey Announces Dr. Christina Restrepo, DVM Achieves Diplomate Status With the American College of Veterinary Dermatology 2Health News:ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results on September 9 2Health News:ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results on September 9 3Health News:ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results on September 9 4Health News:Inventor of Green Catalysts Offers Solutions for Cleaning Toxins and Pollutants in the Environment 2
(Date:10/22/2014)... , Oct. 22, 2014  Paper Pak ... has developed APLS ® Body Guard Bio, ... the spread of bacteria and virus while protecting ... Body Guard Bio features a rugged, external nylon ... that create a leak-proof inner chamber that contains ...
(Date:10/22/2014)... , October 22, 2014 ... Disposable Gloves Market (Product type, Form, End user, Application ... Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, ... disposable gloves market. Based on key trends tracked, it ... valued at $7.9 billion by 2020, registering a CAGR ...
(Date:10/22/2014)... 22, 2014  With a vision to ensure ... a Global Pharmaceutical and Biotech manufacturer selects and ... turnkey solution to protect their animal health brand.  ... Photo - http://photos.prnewswire.com/prnh/20141021/153439 ... and aggregated by the Xyntek and Antares solution ...
Breaking Medicine Technology:New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Xyntek and Antares Serialization Solution Protects Pets Too! 2
... , , ... Inc. (Nasdaq: ALXA ) today announced preliminary results from ... in patients with migraine headache. Both AZ-104 dose groups trended ... endpoint, which was defined as pain-relief at the 2-hour time point, ...
... SAN FRANCISCO, Sept. 14 Schering-Plough Corporation (NYSE: ... vicriviroc, its investigational CCR5 receptor antagonist, from an ongoing, ... treatment-experienced HIV-infected patients. The results showed that vicriviroc ... increased CD4 cell counts, and was generally well tolerated ...
Cached Medicine Technology:Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache 2Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache 3Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache 4Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache 5Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients 2Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients 3Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients 4Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients 5
Intact PTH EIA Bone and Mineral Metabolism 021-SDX016 Parathyroid Hormone...
EPO EIA Human Cytokines 021-SDX021 Erythropoietin Anemia...
... Immunoscan MPO-ANCA Kit is an enzyme immunoassay ... in human serum of the subclass of ... to be used as an aid in ... family of autoantibodies associated with vasculitic disorders ...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-48 Proteinase...
Medicine Products: